Atripla/Vonavir
HIV regimens can be complicated. Most regimens require taking number of pills each day. Some medications are taken on an empty stomach while others are to be taken with meals. HIV infected persons who are sick, who are experiencing HIV symptoms or the negative side effects of their medications. A quality patient-provider relationship can also be identified as an important source of adhering to HIV medications. Understanding the predicament of the majority of HIV positive persons, conceived a breakthrough in HIV treatment administration. Surely, there are ways anyone can do to better adhere to ones treatment regimens but Atripla/Vonavir took all the burden away.
Atripla is the first ever once-daily single tablet regimen (STR) for HIV infection in adults. It was approved by the Food and Drugs Administration on July 12, 2006. Atripla is the result of unprecedented effort between Gilead Sciences the manufacturer of Emtriva and Viread, with Bristol-Myers Squibb the maker of Sustiva.It combines Gilead Science’s tenofovir and emtricitabine with Bristol-Myer Squibb’s efavirenz into a fixed dose pill. Dosing of Atripla is suitable to be taken at bedtime to improve tolerability of the nervous system and it is not recommended for HIV patients under 18 years old.
Mild to moderate rash is a common side effect of efavirenz. In controlled clinical trials, 26% of patients treated with efavirenz experienced new-onset skin rash compared with 17% of patients treated in control groups. Skin discoloration, associated with emtricitabine, may also occur. ATRIPLA should be discontinued in patients developing severe rash associated with blistering, desquamation, mucosal involvement, or fever. Atripla can significantly simplify HIV/AIDS medication regimen by reducing the pill burden, helping to increase adherence and thus reducing potential development of viral resistance to the drugs. This may result in longer term effectiveness of the drug regimen. Learn more, what does hiv stand for
Related Articles
- No related posts
Comments
Leave a Reply